Navigating the winding road toward precision prostate cancer care

Area of Science:

• Oncology
• Genomics
• Biotechnology

Background:

• Prostate cancer (PCa) is a leading cause of cancer mortality in U.S. men.
• Metastatic castration-resistant prostate cancer (mCRPC) poses significant treatment challenges despite androgen-receptor (AR)-targeted therapies.

Purpose of the Study:

• To review key developments in biomarker-driven therapies for mCRPC.
• To outline opportunities and challenges in advancing prostate cancer precision medicine.
• To propose a roadmap for utilizing multi-omics data and AI/ML in PCa research.

Main Methods:

• Review of recent advancements in biomarker-guided therapies for mCRPC.
• Analysis of current challenges and future opportunities in prostate cancer precision medicine.
• Conceptual framework for integrating multi-omics data with AI/ML for preclinical model development.

Main Results:

• Biomarker-driven therapies have significantly expanded treatment options for mCRPC.
• Precision oncology is transforming prostate cancer care.
• AI/ML and multi-omics data hold potential for accelerating translational research.

Conclusions:

• Continued advancements in precision oncology are crucial for improving mCRPC outcomes.
• Leveraging multi-omics data and AI/ML can accelerate the development of novel therapies and preclinical models.
• A strategic roadmap is needed to translate laboratory discoveries into clinical practice for mCRPC patients.